Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer.
_________
The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients.
"This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial cancer, a disease characterized by a paucity of advances in decades," said lead author Matthew Galsky, MD, Co-Director of the Center of Excellence for Bladder Cancer at Mount Sinai.